These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26265385)

  • 21. Hepatitis B: a "GLOBAL" health challenge.
    Fontana RJ
    Gastroenterology; 2009 Feb; 136(2):389-92. PubMed ID: 19109963
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacological properties and clinical efficacy of entecavir monohydrate (Baraclude Tablet 0.5 mg), an anti-HBV drug].
    Amano M; Goto A
    Nihon Yakurigaku Zasshi; 2007 Apr; 129(4):287-97. PubMed ID: 17435342
    [No Abstract]   [Full Text] [Related]  

  • 23. Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients.
    Simonetti G; Gitto S; Golfieri L; Gamal N; Loggi E; Taruschio G; Cursaro C; Nunzella S; Grandi S; Andreone P
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):14-20. PubMed ID: 29064847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current developments in nucleoside/nucleotide analogues for hepatitis B.
    Lo AO; Wong GL
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):607-22. PubMed ID: 24787673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity.
    Hu Y; Cheng X; Cao F; Huang A; Tavis JE
    Antiviral Res; 2013 Sep; 99(3):221-9. PubMed ID: 23796982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
    World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nucleoside/nucleotide analogue treatment].
    Hige S; Ozeki I; Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():516-20. PubMed ID: 26845988
    [No Abstract]   [Full Text] [Related]  

  • 28. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of hepatitis B virus replication in Tupaia hepatocytes by tumor necrosis factor alpha of Tupaia belangeri.
    Xu Y; Köck J; Lu Y; Yang D; Lu M; Zhao X
    Comp Immunol Microbiol Infect Dis; 2011 Jul; 34(4):361-8. PubMed ID: 21684599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic hepatitis B: who to treat and which choice of treatment?
    Di Marco V; Craxì A
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):281-91. PubMed ID: 19344242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview.
    Jia H; Rai D; Zhan P; Chen X; Jiang X; Liu X
    Future Med Chem; 2015; 7(5):587-607. PubMed ID: 25921400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Problems of resistance during treatment of chronic hepapitis B with nucleoside and nucleotide analogues: diagnostics, prophylactics and treatment].
    Abdurakhmanov DT
    Eksp Klin Gastroenterol; 2007; (4):74-81. PubMed ID: 18411444
    [No Abstract]   [Full Text] [Related]  

  • 33. Hepatitis B virus therapy: What's the future holding for us?
    Manzoor S; Saalim M; Imran M; Resham S; Ashraf J
    World J Gastroenterol; 2015 Nov; 21(44):12558-75. PubMed ID: 26640332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
    Papatheodoridis GV; Dimou E; Papadimitropoulos V
    Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
    Lok AS; Zoulim F; Locarnini S; Bartholomeusz A; Ghany MG; Pawlotsky JM; Liaw YF; Mizokami M; Kuiken C;
    Hepatology; 2007 Jul; 46(1):254-65. PubMed ID: 17596850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.
    Lewin S; Walters T; Locarnini S
    Antiviral Res; 2002 Sep; 55(3):381-96. PubMed ID: 12206877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
    Asselah T; Marcellin P
    Clin Liver Dis; 2013 Aug; 17(3):445-50. PubMed ID: 23905815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?
    Degertekin B; Lok AS
    J Hepatol; 2008 Jun; 48(6):892-4. PubMed ID: 18433924
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment in every detected virus replication. New guideline for therapy of hepatitis B publicized].
    MMW Fortschr Med; 2007 Jul; 149(29-30):61. PubMed ID: 17703695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.